The organization will promote public awareness of cfDNA-based NIPT, encourage legislation supporting testing, and push for reimbursement policy changes.
Natera alleges that Bio-Reference broke a contract by promoting a NIPS test based on Illumina technology over Panorama.
The revenue surge was largely due to revenues from Bio-Reference Laboratories, which Opko acquired in August 2015.
Following the close of the deal, Opko's diagnostic services will be merged with Bio-Reference's operations.
Bio-Reference Laboratories, Cepheid, Exact Sciences, and NanoString all saw their shares rise in June. Sequenom topped the list of decliners.
The deal is still subject to other closing conditions including the approval of BRL's shareholders.
The firm said that revenues per patient were up 3 percent, while the number of patients served grew 8 percent.
Opko plans to leverage BRL's national marketing, sales, and distribution resources to enhance the sale of its blood-based 4Kscore test for aggressive prostate cancer.
The company has amended and restated a credit facility and a secured revolving note to increase the available borrowing amount for each to up to $120 million.
The company's CEO noted the recent launches of new NGS cancer panels and said that more genomics offerings are planned for the year.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.